Ignite Creation Date:
2024-05-06 @ 4:03 PM
Last Modification Date:
2024-10-26 @ 2:02 PM
Study NCT ID:
NCT04853602
Status:
AVAILABLE
Last Update Posted:
2024-02-23
First Post:
2021-04-16
Brief Title:
IFx-Hu20 Expanded Access Program
Sponsor:
TuHURA Biosciences Inc
Organization:
TuHURA Biosciences Inc
Study Overview
Official Title:
IFx-Hu20 Expanded Access Program
Status:
AVAILABLE
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Expanded access requests for IFx-Hu20 may be considered for the treatment of adult patients greater than or equal to 18 years of age with stage III through IV cutaneous melanoma advanced Merkel cell carcinoma MCC or advanced cutaneous squamous cell carcinoma cSCC who have failed all available treatment options
To request access use Responsible Party contact information provided in this record
To request access use Responsible Party contact information provided in this record
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None